Búsqueda de Publicación - Prisma - Unidad de Bibliometría

Publicaciones en la fuente LANCET ONCOLOGY

Tipo Año Título Fuente
Artículo2023Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 studyLANCET ONCOLOGY
Nota2023Development of a centralised triage centre for children with cancer and blood disorders in response to the humanitarian crisis in UkraineLANCET ONCOLOGY
Artículo2023Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot studyLANCET ONCOLOGY
Artículo2023Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002) a randomised, double-blind, phase 3 trialLANCET ONCOLOGY
Artículo2023Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration studyLANCET ONCOLOGY
Artículo2022Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 studyLANCET ONCOLOGY
Artículo2022Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trialLANCET ONCOLOGY
Revisión2022Response assessment in paediatric intracranial ependymoma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working groupLANCET ONCOLOGY
Artículo2022Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trialLANCET ONCOLOGY
Artículo2021Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study.LANCET ONCOLOGY
Artículo2020Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trialLANCET ONCOLOGY
Artículo2020Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trialLANCET ONCOLOGY
Artículo2020Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trialLANCET ONCOLOGY
Revisión20192019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancerLANCET ONCOLOGY
Artículo2019Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trialLANCET ONCOLOGY
Artículo2019Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trialLANCET ONCOLOGY
Artículo2019Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trialLANCET ONCOLOGY
Artículo2016Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialLANCET ONCOLOGY
Artículo2012Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLANCET ONCOLOGY
Artículo2011No paradox, no progress: inverse cancer comorbidity in people with other complex diseasesLANCET ONCOLOGY